ISRCTN69686930 https://doi.org/10.1186/ISRCTN69686930

Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia

Submission date	Recruitment status	[_] Prospectively registered
19/05/2010	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
19/05/2010	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
11/08/2015	Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Davis Dutka

Contact details
University of Cambridge
Addenbrookes Hospital
Hills Road
Cambridge
United Kingdom
CB2 2QQ

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
6562

Study information

Scientific Title
Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia

Acronym
GLP-1 and left ventricular function during ischaemia

Study objectives
The hypothesis is that infusion of glucagon-like peptide-1 will protect the heart from ischaemia and improve left ventricular (LV) function during dobutamine stress echocardiography in patients with coronary artery disease

Ethics approval required
Old ethics approval format

Ethics approval(s)
MREC approved, ref: 08/H0304/68

Study design
Single-centre non-randomised interventional treatment trial

Primary study design
Interventional

Secondary study design
Non randomised study

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

Interventions
In the active DSE, patients will receive an infusion of GLP-1 intravenously at 1.2 pmol/kg/min starting 30 minutes prior to the DSE and continuing for 30 minutes into recovery. In the control scan there will be no infusion.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Glucagon-like peptide-1

Primary outcome measure
Global LV function at peak stress

Secondary outcome measures
1. Global LV function at 30 minutes recovery
2. Regional wall LV function at 30 minutes recovery
3. Regional wall LV function at peak stress

Overall study start date
17/06/2009

Completion date
30/07/2010

Eligibility

Key inclusion criteria
Not provided at time of registration

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Planned sample size: 30; UK sample size: 30

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
17/06/2009

Date of final enrolment
30/07/2010

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
University of Cambridge
Cambridge
United Kingdom
CB2 2QQ

Sponsor information

Organisation
Cambridge University Hospitals NHS Foundation Trust (UK)

Sponsor details
Addenbrookes Hospital
Hills Road
Cambridge
England
United Kingdom
CB2 2QQ

Sponsor type
Hospital/treatment centre

Website
http://www.cuh.org.uk/

ROR
https://ror.org/04v54gj93

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2012		Yes	No
Results article	results	08/08/2015		Yes	No